A Phase 2 interventional study of RNS60 and Saline in Hip Labral Tear, sponsored by Revalesio Corporation. Withdrawn at 1 site in United States. Per ClinicalTrials.gov, last updated 2015-02-06.
Sponsored by Revalesio Corporation · Phase 2, Interventional, and Treatment
The purpose of this study is to see if use of RNS60 during hip labral repair surgery decreases pain and improves functional capacity post-operation.
Revalesio Corporation is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Drug: RNS60
Drug: Saline
Assessment of post-operative pain
Comparison of scores from validated pain scales from post-surgery to one week.
Time frame: 1 week
This study is withdrawn, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Revalesio Corporation